Bank of New York Mellon’s Editas Medicine EDIT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $851K | Sell |
262,625
-9,942
| -4% | -$29.1K | ﹤0.01% | 3458 |
|
|
2026
Q1 | $673K | Buy |
272,567
+27,225
| +11% | +$57.6K | ﹤0.01% | 3450 |
|
|
2025
Q4 | $503K | Sell |
245,342
-19,345
| -7% | -$55.8K | ﹤0.01% | 3612 |
|
|
2025
Q3 | $918K | Buy |
264,687
+21,260
| +9% | +$59.3K | ﹤0.01% | 3255 |
|
|
2025
Q2 | $536K | Buy |
243,427
+9,476
| +4% | +$15.5K | ﹤0.01% | 3473 |
|
|
2025
Q1 | $271K | Sell |
233,951
-9,425
| -4% | -$13.9K | ﹤0.01% | 3748 |
|
|
2024
Q4 | $309K | Buy |
243,376
+463
| +0.2% | +$1.18K | ﹤0.01% | 3770 |
|
|
2024
Q3 | $828K | Sell |
242,913
-53,241
| -18% | -$232K | ﹤0.01% | 3245 |
|
|
2024
Q2 | $1.38M | Buy |
296,154
+11,332
| +4% | +$63.9K | ﹤0.01% | 3002 |
|
|
2024
Q1 | $2.11M | Sell |
284,822
-28,440
| -9% | -$236K | ﹤0.01% | 2740 |
|
|
2023
Q4 | $3.17M | Sell |
313,262
-972
| -0.3% | -$8.53K | ﹤0.01% | 2596 |
|
|
2023
Q3 | $2.45M | Buy |
314,234
+39,076
| +14% | +$335K | ﹤0.01% | 2692 |
|
|
2023
Q2 | $2.26M | Buy |
275,158
+11,491
| +4% | +$100K | ﹤0.01% | 2765 |
|
|
2023
Q1 | $1.91M | Buy |
263,667
+6,882
| +3% | +$61.2K | ﹤0.01% | 2830 |
|
|
2022
Q4 | $2.28M | Buy |
256,785
+3,494
| +1% | +$38.4K | ﹤0.01% | 2789 |
|
|
2022
Q3 | $3.1M | Buy |
253,291
+20,327
| +9% | +$317K | ﹤0.01% | 2567 |
|
|
2022
Q2 | $2.76M | Sell |
232,964
-55,914
| -19% | -$749K | ﹤0.01% | 2654 |
|
|
2022
Q1 | $5.49M | Buy |
288,878
+1,060
| +0.4% | +$19.7K | ﹤0.01% | 2372 |
|
|
2021
Q4 | $7.64M | Sell |
287,818
-13,643
| -5% | -$470K | ﹤0.01% | 2246 |
|
|
2021
Q3 | $12.4M | Buy |
301,461
+28,207
| +10% | +$1.55M | ﹤0.01% | 2006 |
|
|
2021
Q2 | $15.5M | Buy |
273,254
+19,212
| +8% | +$710K | ﹤0.01% | 1878 |
|
|
2021
Q1 | $10.7M | Sell |
254,042
-25,952
| -9% | -$1.48M | ﹤0.01% | 2048 |
|
|
2020
Q4 | $19.6M | Buy |
279,994
+30,215
| +12% | +$1.24M | ﹤0.01% | 1647 |
|
|
2020
Q3 | $7.01M | Sell |
249,779
-66,582
| -21% | -$2.17M | ﹤0.01% | 2046 |
|
|
2020
Q2 | $9.36M | Buy |
316,361
+60,383
| +24% | +$1.58M | ﹤0.01% | 1871 |
|
|
2020
Q1 | $5.08M | Sell |
255,978
-3,866
| -1% | -$97.5K | ﹤0.01% | 2066 |
|
|
2019
Q4 | $7.69M | Buy |
259,844
+9,461
| +4% | +$236K | ﹤0.01% | 2124 |
|
|
2019
Q3 | $5.69M | Buy |
250,383
+42,580
| +20% | +$1.05M | ﹤0.01% | 2218 |
|
|
2019
Q2 | $5.14M | Sell |
207,803
-12,304
| -6% | -$294K | ﹤0.01% | 2315 |
|
|
2019
Q1 | $5.38M | Buy |
220,107
+19,605
| +10% | +$444K | ﹤0.01% | 2300 |
|
|
2018
Q4 | $4.56M | Buy |
200,502
+1,651
| +0.8% | +$44.9K | ﹤0.01% | 2352 |
|
|
2018
Q3 | $6.33M | Buy |
198,851
+5,579
| +3% | +$180K | ﹤0.01% | 2287 |
|
|
2018
Q2 | $6.92M | Sell |
193,272
-10,683
| -5% | -$378K | ﹤0.01% | 2217 |
|
|
2018
Q1 | $6.76M | Buy |
203,955
+44,654
| +28% | +$1.59M | ﹤0.01% | 2190 |
|
|
2017
Q4 | $4.89M | Sell |
159,301
-8,914
| -5% | -$224K | ﹤0.01% | 2372 |
|
|
2017
Q3 | $4.04M | Buy |
168,215
+26,093
| +18% | +$497K | ﹤0.01% | 2446 |
|
|
2017
Q2 | $2.38M | Buy |
142,122
+78,632
| +124% | +$1.42M | ﹤0.01% | 2747 |
|
|
2017
Q1 | $1.42M | Buy |
63,490
+22,061
| +53% | +$457K | ﹤0.01% | 3055 |
|
|
2016
Q4 | $672K | Buy |
41,429
+2,878
| +7% | +$43.7K | ﹤0.01% | 3452 |
|
|
2016
Q3 | $520K | Buy |
38,551
+10,812
| +39% | +$222K | ﹤0.01% | 3514 |
|
|
2016
Q2 | $677K | Buy |
27,739
+10,514
| +61% | +$355K | ﹤0.01% | 3382 |
|
|
2016
Q1 | $595K | Buy |
+17,225
| New | +$453K | ﹤0.01% | 3355 |
|
Other funds holding EDIT
GCP
EAM
Bank of New York Mellon's EDIT Position: Q2 2026 in Review
Bank of New York Mellon reduced its Editas Medicine (EDIT) stake by 3.6% in Q2 2026, selling an estimated $29.1K and leaving 262,625 shares worth $851K. The position accounts for ﹤0.01% of the portfolio, ranked #3458.
Bank of New York Mellon first reported a position in EDIT in Q1 2016 and has held it in 42 quarters since. The position peaked at $19.6M in Q4 2020. 86 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.
- Bank of New York Mellon held 262,625 shares of Editas Medicine worth $851K as of Q2 2026.
- Bank of New York Mellon sold 9,942 Editas Medicine shares in Q2 2026, an estimated $29.1K.
- Editas Medicine made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3458 holding.
- Bank of New York Mellon first reported a position in Editas Medicine in Q1 2016 and has held it in 42 quarters since.
- Bank of New York Mellon's Editas Medicine position peaked at $19.6M in Q4 2020.
- 86 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.
Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.